FindTrial
Sign In

Yoga intervention for patients with systemic Lupus erythematous

Effectiveness of yoga intervention on the levels of autoantibodies, inflammatory epigenetic markers and quality of life in women with systemic lupus erythematous.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/05/033419
Enrollment
128
Registered
2021-05-06
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E888- Other specified metabolic disorders

Interventions

Intervention1: YOGA: A specific Yoga module by Middleton KR et al, 2018 for Systemic Lupus Erythematous will be used in this study. Video of yoga session recorded by experts will be shared among the p

Sponsors

Dr Shobana
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: New cases- All SLE patients fulfill the revised ACR classification criteria malar and discoid rash, photosensitivity, oral ulcers, arthritis, serositis, renal, neurological, hematologic and immunologic disorder, and positive antinuclear antibody. The presence of 4 out of 11 criteria is confirmed to be the diagnosis of SLE. Resistant case- SLE patients unresponsive to previous treatment with one/ more successive/ simultaneous conventional immunosuppressive drugs for more than 6 months or had continuing requirement for a daily dose of �20 mg of steroids or its equivalent

Exclusion criteria

Exclusion criteria: Patients with severe form of SLE ï?¶ ââ??ª Patients with any other Inflammatory disorder & immune deficiency disorder. ï?¶ ââ??ª Patients with confirmed HIV infection ï?¶ ââ??ª Patients with acute infectious diseases & metastatic diseases ï?¶ ââ??ª Patients with Associated co-morbidity or depression or psychological illnesses ï?¶ ââ??ª Practicing yoga in the past 3 months

Design outcomes

Primary

MeasureTime frame
Routine markers- Hb, WBC, DC, ESR, Urine R/E (preferably a fresh sample examined), Serum chemistry (urea, creatinine, liver function tests, lipid profile), Autoantibodies and complement- ANA, anti-dsDNA, anti-cardiolipin, C3, C4, Inflammatory markers: IL-6, IL-10, IL-17, TNF-alpha, Interferon-gamma Micro RNATimepoint: All the above parameters are measured at baseline and again at the end of intervention period i.e after 6 months.—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Shobana

Sri Ramachandra Medical College and Research Institute

shobana.r@sriramachandra.edu.in09840012288

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026